Novo Nordisk, Torrent Pharma expand insulin capacity in Gujarat by 35%

Torrent invested Rs 60 cr in its insulin manufacturing facility at Indrad so far, which had been set up in partnership with Novo Nordisk India in 2009

The world's largest maker of diabetes drugs Denmark-based Novo Nordisk and also the market leader in India for insulin products, is upping its game in the diabetes capital. In partnership with Torrent Pharmaceuticals, Novo Nordisk today inaugurated the extended insulin manufacturing facility at the latter’s Indrad factory near Ahmedabad. With this expansion, the company aims to add another two million patients under its insulin therapy. 

The Danish major currently enjoys around 60% market share in the Rs 2,200-crore insulin market in India, which is currently growing at a 15-17% rate. Around 3 million people currently have access to its insulin